INTRODUCTION
L IVER FIBROSIS REPRESENTS the organ's response to an injury event which results in a scarring process with deposition of collagen and matrix proteins. Several chronic liver diseases can induce liver fibrosis, among them chronic viral hepatitis B and hepatitis C (HCV), alcoholic liver disease, and non-alcoholic fatty liver disease (NAFLD).
When not spontaneously resolved, HCV infection can develop into a chronic form which, if left untreated, increases the liver damage and fibrosis and may eventually progress into cirrhosis and hepatocellular carcinoma (HCC). The pathogenesis of these multiple stages is a very complex and multifactorial phenomenon influenced by environmental (age, gender, etc.), behavioral (alcohol and drug abuse, smoking, diet etc.), and genetic factors, primarily single nucleotide polymorphisms (SNPs) that affect different genes predisposing an individual to the disease. 1 The first choice therapy in HCV infection is the treatment with pegylated interferon (PEG-IFN) and ribavirin 2 or other antivirals in combination with IFN or on their own, for example, simeprevir, sofosbuvir, and daclatasvir. The success of this approach varies from patient to patient and relies on the genotype of the virus. Moreover, the therapy can last up to 48 weeks and is extremely costly.
The understanding of the host genetic factors that correlate HCV infection to liver fibrosis remains largely unknown. Several genome-wide association studies (GWAS) have been carried out in HCV-infected patient cohorts finding, for example, variants associated to the immune response in the clearance of the virus like the interleukin-28B cluster. 3 More recently, the SNP rs4374383 has been found associated with significantly reduced risk of developing HCV-induced liver fibrosis 4 and linked to fibrosis progression in patients with NAFLD. 5 It is generally assumed that most of the genetic association to a disease is mediated by a genomic regulatory element at which an SNP causes the differential binding of a transcription factor (TF) to the two alleles, or variants, thereby affecting the activity of a gene. The variants identified by GWAS are usually not the drivers of the observed association. 6 The top SNP associated to HCV-induced liver fibrosis is not located in a regulatory element and therefore not likely to mediate the association. In this study, we therefore utilized the TF binding data from The Encyclopedia of DNA Elements (ENCODE) 7 chromatin immunoprecipitation sequencing (ChIP-seq) experiments in the epithelial HCC cell line HepG2 to identify putative regulatory variants that showed an allele-specific TF binding (AS-SNPs) and that are in high linkage disequilibrium (LD) with the top GWAS SNP, and consequently likely drivers of the association to HCV-induced liver fibrosis.
METHODS
Allele-specific SNP definition W E IDENTIFIED A collection of AS-SNPs in the HepG2 cell line following our established bioinformatics pipeline 8 that uses HepG2 TF ChIP-seq raw reads data (.fastq), obtained from the ENCODE project database (ftp://hgdownload.cse.ucsc.edu/goldenPath/hg19/ encodeDCC/), to pinpoint heterozygous positions that show a statistically significant preferential binding of TFs to one of the alleles (see Cavalli et al. 9 for a detailed description of the pipeline). We then intersected our collection of liver-specific AS-SNPs with GWAS SNPs associated to liver fibrosis (National Human Genome Research Institute GWAS catalog at January 2014) 10 and SNPs in LD (r 2 > 0.8) with these. Proxy SNPs were calculated by the SNAP tool 11 which uses genotype data from the International HapMap Project to select candidate functional AS-SNPs for experimental validation.
Cell cultures
HepG2 cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated fetal bovine serum, L-glutamine, and a solution stabilized with 10 000 units penicillin and 10 mg streptomycin/mL and sterile-filtered BioReagent, suitable for cell culture (Sigma-Aldrich, St. Louis, MO, USA), at 37°C with 5% CO 2 .
Construction of cloning plasmids and luciferase reporter assays
All the luciferase expression constructs were built based on pGL4.23 from Promega, Fitchburg, WI, USA, Fitchburg, WI, USA. Genomic sequences surrounding rs6726639 were amplified by Phusion Hot Start Flex DNA polymerase (New England Biolabs, Ipswich, MA, USA) using HepG2 genomic DNA as template (Table S1 , Figure S1 ). The amplified fragments were inserted upstream of the minimal promoter sequence of pGL4.23 by SLiCE cloning methods.
12 HepG2 cells were transfected 1 day after plating with approximately 90% confluence in a 96-well plate. Each well was transfected with 100 ng firefly luciferase reporter vector harboring respective rs6726639 alleles together with 1 ng Renilla luciferase reporter vector pGL4.74. Twenty-four hours after transfection, firefly and luciferase activity were measured by the Dual-Luciferase Reporter Assay System (Promega) on an Infinite M200 PRO reader (Tecan, Männedorf, Switzerland) following instructions provided by the manufacturer. More details are available in the Extended Methods section in Supporting Information.
Electrophoresis mobility shift assay
Oligonucleotides probes were designed (Table S1 ) with both alleles of rs6726639 flanked by 14 bp in both cold and 5′-biotinylated form. For the binding reaction, 3-6 μg HepG2 nuclear extract was incubated with 200 fmol each biotinylated double-stranded DNA probe for 40 min on ice. For the competition assays, 20 pmol unlabeled double-stranded DNA probes were added to the binding reaction; 2 μg anti-interferon regulatory factor 1 (IRF1) antibody (sc-497 X; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) was added for supershift reactions. DNA-protein complexes were cross-linked using UV light and detected by chemiluminescence using LightShift Chemiluminescent electrophoresis mobility shift assay (EMSA) Kit (Thermo Scientific). More details available in the Extended Methods section in Supporting Information.
RESULTS AND DISCUSSION
H EPATITIS C-INDUCED LIVER fibrosis is associated with rs4374383. 4 However, this GWAS SNP is not located in a regulatory element and 72 SNPs are in high LD (r 2 > 0.8) with it, making it laborious to Novel regulatory SNP linked to liver fibrosis 827 Hepatology Research 2017; 47: 826-830 Relative luciferase activity (RLU) values were normalized to the empty control vector pGL4.23. ***P < 0.0001; **P < 0.001; *P < 0.01; ns, not significant. (e) EMSA supershift. Left panel, the interferon regulatory factor 1 (IRF1) motif was identified using the Tomtom tool. experimentally test each to find the functional variant (Fig. 1a) . One of these associated SNPs is the AS-SNP rs6726639 (r 2 = 0.94) located in a regulatory element in the 8th intron of the c-mer proto-oncogene tyrosine kinase (MERTK) gene, which is upregulated in many cancers. Development of liver fibrosis predisposes to HCC, suggesting that this pathway might contribute to both diseases. At rs6726639 ChIP-seq of HNF4α gave 25 reads for the A and 3 for the C allele (Fig. 1b) , showing a statistically significant allele binding bias (see Methods). Reads from 17 other TFs ChIP-sequenced in the ENCODE project also showed a preference for the A allele, although without statistical significance after correction for multiple testing. We tested both alleles using EMSA and found a stronger band for the A than the C allele consistent with the ChIP-seq result, suggesting that a TF binds stronger to the A allele (Fig. 1c) . Lane 6 in Figure 1(c) indicates that the C allele binds some protein, which explains why a 100× excess of this cold allele can compete out the binding to the A allele in lane 4 in Figure 1 (c). When testing both alleles in luciferase assays for functional effect, we found a significantly lower signal for the A than the C allele, indicating that a TF that is a transcriptional repressor binds better to the A allele (Fig. 1d) . Analyses of the phased data of 1092 individuals sequenced by the 1000 Genomes project 14 revealed that the A allele of the GWAS SNP rs4374383, associated with significantly reduced risk of developing liver fibrosis, 4 is on the same haplotype as the A allele of rs6726639, which had low enhancer activity in the luciferase assay. This suggests that the low activity A allele could represent the binding site of a TF whose activity may protect against both liver fibrosis and HCC. The repressory behavior shown by the A allele is also in agreement with the low MERTK expression associated to the A allele of rs6726639 in the adrenal gland reported by The GTEx project. 15 Low expression of MERTK has also been associated to the A genotype of rs4374383 in liver biopsies from Italian subjects who were morbidly obese as well as in cases with NAFLD. 5 Interferon-α is used to treat hepatitis C to prevent fibrosis and cancer and it is known to regulate the expression of several TFs. Among others, IFN upregulates IRF1 16 encoding IRF1. Motif analyses 13 revealed binding sites for TFs belonging to the IRF family overlapping rs6726639. In particular, we observed how the binding of IRF1 could be disrupted by the SNP in EMSA supershift experiments in which the signal intensity of the binding at the A allele was decreased after incubation with an antibody against IRF1 (Fig. 1e) . This suggests that IRF1 preferentially binds the A allele and may downregulate MERTK, providing a molecular explanation for the INF treatment effect. This is in agreement with the weaker binding to the C allele. IRF1 is expressed in liver cells, so the same mechanism may be in place also in subjects not treated with IFN and may contribute to variation in liver fibrosis associated with NAFLD and other conditions.
CONCLUSIONS
O UR DATA SUGGEST a novel putative molecular mechanism that could contribute to explain the complex etiology of viral liver fibrosis: treatment of HCV infection with IFN results in an increase of IRF1 levels. Preferential binding of IRF1 to the rs6726639 A allele, in turn, acts as a repressor of MERTK activity, diminishing the risk of fibrosis development and eventually the onset of HCC.
SUPPORTING INFORMATION
A DDITIONAL SUPPORTING INFORMATION may be found in the online version of this article at the publisher's web site:
Data S1 Extended Methods section. Table S1 Oligonucleotide sequences used in this study. Figure S1 UCSC genome browser view of the AS-SNP rs6726639.
